Diseases /
Prostate Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: One of the most common malignant tumors afflicting men. The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland. Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes. Adenocarcinomas represent the overwhelming majority of prostatic carcinomas. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease. [1]
Prostate carcinomas most frequently harbor alterations in TP53, TMPRSS2, ERG, PTEN, and AR [2].
TMPRSS2-ERG Fusion, TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and AR Amplification are the most common alterations in prostate carcinoma [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for prostate carcinoma, 2 are FDA-approved in at least one setting and 2 have NCCN guidelines in at least one setting [3].
Olaparib +
Disease is predicted to be sensitive: -
Biomarker Criteria:
Sample must match one or more of the following:
ATM Mutation, BRCA1 Mutation, BRCA2 Mutation, FANCL Mutation, PALB2 Mutation, ATM Loss, BARD1 Loss, BARD1 Mutation, BRCA1 Loss, BRCA2 Loss, BRIP1 Loss, BRIP1 Mutation, CDK12 Loss, CDK12 Mutation, CHEK1 Loss, CHEK1 Mutation, CHEK2 Loss, CHEK2 Mutation, FANCL Loss, PALB2 Loss, RAD51B Loss, RAD51B Mutation, RAD51C Loss, RAD51C Mutation, RAD51D Loss, RAD51D Mutation, RAD54L Loss, RAD54L Mutation |
Clinical Setting(s): Metastatic (FDA, NCCN) |
Note: Approved for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. |
Rucaparib +
Disease is predicted to be sensitive: -
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
Note: Indicated for deleterious BRCA mutations (germline and/or somatic) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. |
Clinical Trials
There are 241 clinical trials for prostate carcinoma, of which 195 are open and 46 are completed or closed. Of the trials that contain prostate carcinoma as an inclusion criterion, 5 are early phase 1 (5 open), 76 are phase 1 (51 open), 48 are phase 1/phase 2 (41 open), 71 are phase 2 (64 open), 20 are phase 3 (18 open), 2 are phase 4 (2 open), and 19 are no phase specified (14 open).
BRCA1, BRCA2, and ATM are the most frequent gene inclusion criteria for prostate carcinoma clinical trials [3].
Enzalutamide, docetaxel, and prednisone are the most common interventions in prostate carcinoma clinical trials.
Significant Genes in Prostate Carcinoma
AKT1 +
AKT1 is altered in 1.9% of prostate carcinoma patients [2].
AKT1 is an inclusion eligibility criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [3].
AKT2 +
AKT2 is altered in 0.87% of prostate carcinoma patients [2].
AKT2 is an inclusion eligibility criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT2 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [3].
AKT3 +
AKT3 is altered in 0.53% of prostate carcinoma patients [2].
AKT3 is an inclusion eligibility criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [3].
ARID1A +
ARID1A is altered in 2.81% of prostate carcinoma patients [2].
ARID1A is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ARID1A status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
ATM +
ATM is altered in 5.76% of prostate carcinoma patients [2].
ATM is an inclusion eligibility criterion in 23 clinical trials for prostate carcinoma, of which 19 are open and 4 are closed. Of the trials that contain ATM status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 14 are phase 2 (12 open), and 2 are phase 3 (2 open) [3].
Olaparib has evidence of efficacy in patients with ATM mutation in prostate carcinoma [3].
ATR +
ATR is altered in 2.11% of prostate carcinoma patients [2].
ATR is an inclusion eligibility criterion in 12 clinical trials for prostate carcinoma, of which 9 are open and 3 are closed. Of the trials that contain ATR status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
ATRX +
ATRX is altered in 1.08% of prostate carcinoma patients [2].
ATRX is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ATRX status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
BACH1 +
BACH1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BACH1 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
BARD1 +
BARD1 is altered in 0.67% of prostate carcinoma patients [2].
BARD1 is an inclusion eligibility criterion in 17 clinical trials for prostate carcinoma, of which 14 are open and 3 are closed. Of the trials that contain BARD1 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with BARD1 mutation in prostate carcinoma [3].
BRCA1 +
BRCA1 is altered in 1.24% of prostate carcinoma patients [2].
BRCA1 is an inclusion eligibility criterion in 25 clinical trials for prostate carcinoma, of which 21 are open and 4 are closed. Of the trials that contain BRCA1 status and prostate carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].
Olaparib and rucaparib have evidence of efficacy in patients with BRCA1 mutation in prostate carcinoma [3].
BRCA2 +
BRCA2 is altered in 6.61% of prostate carcinoma patients [2].
BRCA2 is an inclusion eligibility criterion in 25 clinical trials for prostate carcinoma, of which 21 are open and 4 are closed. Of the trials that contain BRCA2 status and prostate carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].
Olaparib and rucaparib have evidence of efficacy in patients with BRCA2 mutation in prostate carcinoma [3].
BRIP1 +
BRIP1 is altered in 1.28% of prostate carcinoma patients [2].
BRIP1 is an inclusion eligibility criterion in 19 clinical trials for prostate carcinoma, of which 16 are open and 3 are closed. Of the trials that contain BRIP1 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 11 are phase 2 (10 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with BRIP1 mutation in prostate carcinoma [3].
C11ORF30 +
C11orf30 is altered in 0.28% of prostate carcinoma patients [2].
C11orf30 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain C11orf30 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
CDK12 +
CDK12 is altered in 5.49% of prostate carcinoma patients [2].
CDK12 is an inclusion eligibility criterion in 18 clinical trials for prostate carcinoma, of which 15 are open and 3 are closed. Of the trials that contain CDK12 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (9 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with CDK12 mutation in prostate carcinoma [3].
CDKN2A +
CDKN2A is altered in 2.19% of prostate carcinoma patients [2].
CDKN2A is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
CHEK1 +
CHEK1 is altered in 0.55% of prostate carcinoma patients [2].
CHEK1 is an inclusion eligibility criterion in 15 clinical trials for prostate carcinoma, of which 12 are open and 3 are closed. Of the trials that contain CHEK1 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with CHEK1 mutation in prostate carcinoma [3].
CHEK2 +
CHEK2 is altered in 1.03% of prostate carcinoma patients [2].
CHEK2 is an inclusion eligibility criterion in 16 clinical trials for prostate carcinoma, of which 13 are open and 3 are closed. Of the trials that contain CHEK2 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with CHEK2 mutation in prostate carcinoma [3].
ERBB2 +
ERBB2 is altered in 1.14% of prostate carcinoma patients [2].
ERBB2 is an inclusion eligibility criterion in 4 clinical trials for prostate carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and prostate carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [3].
ERCC2 +
ERCC2 is altered in 1.05% of prostate carcinoma patients [2].
ERCC2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERCC2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
ERCC3 +
ERCC3 is altered in 0.92% of prostate carcinoma patients [2].
ERCC3 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERCC3 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
ERCC4 +
ERCC4 is altered in 0.74% of prostate carcinoma patients [2].
ERCC4 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERCC4 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
ERCC5 +
ERCC5 is altered in 1.66% of prostate carcinoma patients [2].
ERCC5 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERCC5 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
ERCC6 +
ERCC6 is altered in 0.45% of prostate carcinoma patients [2].
ERCC6 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERCC6 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
FANCA +
FANCA is altered in 2.72% of prostate carcinoma patients [2].
FANCA is an inclusion eligibility criterion in 18 clinical trials for prostate carcinoma, of which 15 are open and 3 are closed. Of the trials that contain FANCA status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (9 open), and 1 is phase 3 (1 open) [3].
FANCB +
FANCB is altered in 0.39% of prostate carcinoma patients [2].
FANCB is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain FANCB status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
FANCC +
FANCC is altered in 0.88% of prostate carcinoma patients [2].
FANCC is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain FANCC status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
FANCD2 +
FANCD2 is altered in 1.84% of prostate carcinoma patients [2].
FANCD2 is an inclusion eligibility criterion in 14 clinical trials for prostate carcinoma, of which 11 are open and 3 are closed. Of the trials that contain FANCD2 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
FANCE +
FANCE is altered in 0.5% of prostate carcinoma patients [2].
FANCE is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain FANCE status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
FANCF +
FANCF is altered in 0.74% of prostate carcinoma patients [2].
FANCF is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain FANCF status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
FANCG +
FANCG is altered in 1.44% of prostate carcinoma patients [2].
FANCG is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain FANCG status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
FANCI +
FANCI is altered in 3.23% of prostate carcinoma patients [2].
FANCI is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain FANCI status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
FANCL +
FANCL is altered in 0.98% of prostate carcinoma patients [2].
FANCL is an inclusion eligibility criterion in 15 clinical trials for prostate carcinoma, of which 12 are open and 3 are closed. Of the trials that contain FANCL status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with FANCL mutation in prostate carcinoma [3].
FANCM +
FANCM is altered in 3.54% of prostate carcinoma patients [2].
FANCM is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain FANCM status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain HDAC1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain HDAC2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
HRAS +
HRAS is altered in 1.15% of prostate carcinoma patients [2].
HRAS is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
KRAS +
KRAS is altered in 1.14% of prostate carcinoma patients [2].
KRAS is an inclusion eligibility criterion in 3 clinical trials for prostate carcinoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 7 clinical trials for prostate carcinoma, of which 4 are open and 3 are closed. Of the trials that contain MCPH1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].
MDM2 +
MDM2 is altered in 0.78% of prostate carcinoma patients [2].
MDM2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MDM2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MDM4 +
MDM4 is altered in 1.22% of prostate carcinoma patients [2].
MDM4 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MDM4 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MET +
MET is altered in 1.29% of prostate carcinoma patients [2].
MET is an inclusion eligibility criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MET status and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MLF1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MLH1 +
MLH1 is altered in 0.89% of prostate carcinoma patients [2].
MLH1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MLH1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MLH3 +
MLH3 is altered in 2.77% of prostate carcinoma patients [2].
MLH3 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MLH3 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MRE11A +
MRE11A is altered in 0.96% of prostate carcinoma patients [2].
MRE11A is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain MRE11A status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
MSH2 +
MSH2 is altered in 1.89% of prostate carcinoma patients [2].
MSH2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MSH2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MSH3 +
MSH3 is altered in 2.1% of prostate carcinoma patients [2].
MSH3 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MSH3 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MSH6 +
MSH6 is altered in 1.97% of prostate carcinoma patients [2].
MSH6 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MSH6 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MUTYH +
MUTYH is altered in 0.69% of prostate carcinoma patients [2].
MUTYH is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MUTYH status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
MYC +
MYC is altered in 5.87% of prostate carcinoma patients [2].
MYC is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
NBN +
NBN is altered in 3.34% of prostate carcinoma patients [2].
NBN is an inclusion eligibility criterion in 16 clinical trials for prostate carcinoma, of which 13 are open and 3 are closed. Of the trials that contain NBN status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
NPM1 +
NPM1 is altered in 0.31% of prostate carcinoma patients [2].
NPM1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain NPM1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
NRAS +
NRAS is altered in 0.41% of prostate carcinoma patients [2].
NRAS is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
PALB2 +
PALB2 is altered in 1.41% of prostate carcinoma patients [2].
PALB2 is an inclusion eligibility criterion in 20 clinical trials for prostate carcinoma, of which 17 are open and 3 are closed. Of the trials that contain PALB2 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 12 are phase 2 (11 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with PALB2 mutation in prostate carcinoma [3].
PARP1 +
PARP1 is altered in 0.95% of prostate carcinoma patients [2].
PARP1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PARP1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
PARP2 +
PARP2 is altered in 5.26% of prostate carcinoma patients [2].
PARP2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PARP2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
PDGFRA +
PDGFRA is altered in 1.11% of prostate carcinoma patients [2].
PDGFRA is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
PIK3CA +
PIK3CA is altered in 4.46% of prostate carcinoma patients [2].
PIK3CA is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
PIK3CB +
PIK3CB is altered in 2.28% of prostate carcinoma patients [2].
PIK3CB is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and prostate carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PIK3CG +
PIK3CG is altered in 1.5% of prostate carcinoma patients [2].
PIK3CG is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
PIK3R1 +
PIK3R1 is altered in 2.9% of prostate carcinoma patients [2].
PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
PIK3R2 +
PIK3R2 is altered in 1.46% of prostate carcinoma patients [2].
PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
PMS1 +
PMS1 is altered in 0.7% of prostate carcinoma patients [2].
PMS1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PMS1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
PMS2 +
PMS2 is altered in 1.27% of prostate carcinoma patients [2].
PMS2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PMS2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
POLE +
POLE is altered in 2.5% of prostate carcinoma patients [2].
POLE is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain POLE status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
PPP2R1A +
PPP2R1A is altered in 0.99% of prostate carcinoma patients [2].
PPP2R1A is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PPP2R1A status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 7 clinical trials for prostate carcinoma, of which 6 are open and 1 is closed. Of the trials that contain PPP2R2A status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
PTEN +
PTEN is altered in 17.77% of prostate carcinoma patients [2].
PTEN is an inclusion eligibility criterion in 15 clinical trials for prostate carcinoma, of which 9 are open and 6 are closed. Of the trials that contain PTEN status and prostate carcinoma as inclusion criteria, 5 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 2 are phase 3 (2 open) [3].
RAD50 +
RAD50 is altered in 0.73% of prostate carcinoma patients [2].
RAD50 is an inclusion eligibility criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain RAD50 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [3].
RAD51 +
RAD51 is altered in 0.22% of prostate carcinoma patients [2].
RAD51 is an inclusion eligibility criterion in 16 clinical trials for prostate carcinoma, of which 13 are open and 3 are closed. Of the trials that contain RAD51 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
RAD51B +
RAD51B is altered in 0.46% of prostate carcinoma patients [2].
RAD51B is an inclusion eligibility criterion in 15 clinical trials for prostate carcinoma, of which 12 are open and 3 are closed. Of the trials that contain RAD51B status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with RAD51B mutation in prostate carcinoma [3].
RAD51C +
RAD51C is altered in 0.54% of prostate carcinoma patients [2].
RAD51C is an inclusion eligibility criterion in 18 clinical trials for prostate carcinoma, of which 15 are open and 3 are closed. Of the trials that contain RAD51C status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (9 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with RAD51C mutation in prostate carcinoma [3].
RAD51D +
RAD51D is altered in 0.18% of prostate carcinoma patients [2].
RAD51D is an inclusion eligibility criterion in 17 clinical trials for prostate carcinoma, of which 14 are open and 3 are closed. Of the trials that contain RAD51D status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with RAD51D mutation in prostate carcinoma [3].
RAD54L +
RAD54L is altered in 0.5% of prostate carcinoma patients [2].
RAD54L is an inclusion eligibility criterion in 15 clinical trials for prostate carcinoma, of which 12 are open and 3 are closed. Of the trials that contain RAD54L status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
Olaparib has evidence of efficacy in patients with RAD54L mutation in prostate carcinoma [3].
RB1 +
RB1 is altered in 5.75% of prostate carcinoma patients [2].
RB1 is an inclusion eligibility criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RB1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].
RET +
RET is altered in 1.55% of prostate carcinoma patients [2].
RET is an inclusion eligibility criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
RICTOR +
RICTOR is altered in 1.28% of prostate carcinoma patients [2].
RICTOR is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].
SLX4 +
SLX4 is altered in 2.56% of prostate carcinoma patients [2].
SLX4 is an inclusion eligibility criterion in 12 clinical trials for prostate carcinoma, of which 9 are open and 3 are closed. Of the trials that contain SLX4 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
SMARCB1 +
SMARCB1 is altered in 0.56% of prostate carcinoma patients [2].
SMARCB1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain SMARCB1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
STAG2 +
STAG2 is altered in 1.13% of prostate carcinoma patients [2].
STAG2 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain STAG2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
STK11 +
STK11 is altered in 0.61% of prostate carcinoma patients [2].
STK11 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain STK11 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
TP53 +
TP53 is altered in 28.78% of prostate carcinoma patients [2].
TP53 is an inclusion eligibility criterion in 5 clinical trials for prostate carcinoma, of which 3 are open and 2 are closed. Of the trials that contain TP53 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [3].
WNT5A +
WNT5A is an inclusion eligibility criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains WNT5A status and prostate carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].
XRCC1 +
XRCC1 is altered in 0.79% of prostate carcinoma patients [2].
XRCC1 is an inclusion eligibility criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain XRCC1 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.